Table 4 Clinicopathological characteristics of high- and low-grade regression groups based on ART scores.

From: Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems

 

High-grade regression group (ART score 0, 1, 2, 3)

Low-grade regression group (ART score 4)

P value

No. of patients

32

65

 

Age, years

Median (range)

65 (38–84)

68 (49–78)

 

≥ 70 (%)

10 (31%)

21 (32%)

0.916

Sex, male (%)

18 (56%)

46 (71%)

0.156

Tumor location (%)

Head/body and tail

15 (47%)/17 (53%)

49 (75%)/16 (25%)

0.005*

Preoperative diagnosis (%)

R/BR/LA/M

8 (25%)/16 (50%)/1 (3%)/7 (22%)

22 (34%)/35 (54%)/6 (9%)/2 (3%)

0.027*

Preoperative treatment (%)

CRT/CT

17 (53%)/15 (47%)

25 (38%)/40 (62%)

0.171

Tumor differentiation, n (%)

G1/G2/G3/others

10 (31%)/13 (41%)/3 (9%)/6 (19%)

32 (49%)/28 (43%)/4 (6%)/1 (2%)

0.013*

Vascular invasion (%)

Negative/positive

18 (56%)/14 (44%)

7 (11%)/58 (89%)

 < 0.001*

Perineural invasion (%)

Negative/positive

15 (47%)/17 (53%)

8 (12%)/57 (88%)

 < 0.001*

Stage (UICC 8th) (%)

0/IA/IB/IIA

1 (3%)/14 (44%)/8 (25%)/1(3%)

0 (0%)/6 (9%)/19 (29%)/5 (8%)

0.001*

IIB/III/IV

5 (16%)/2 (6%)/1(3%)

24 (37%)/11 (17%)/0 (0%)

 

Negative resection margin, n (%)

6 (19%)/26(81%)

14 (22%)/51 (78%)

0.750

  1. Gemcitabine- and S-1-based chemotherapies with or without radiation for neoadjuvant treatment.
  2. R, resectable; BR, borderline resectable; LA, locally advanced; M, metastasis; CRT, chemoradiation; CT, chemotherapy; G, histological grade.
  3. *p < 0.05 by chi-square test.